Carneiro Ana, Isinger Anna, Karlsson Anna, Johansson Jan, Jönsson Göran, Bendahl Pär-Ola, Falkenback Dan, Halvarsson Britta, Nilbert Mef
Department of Oncology, Lund University Hospital, 221 85 Lund, Sweden.
BMC Cancer. 2008 Apr 11;8:98. doi: 10.1186/1471-2407-8-98.
Esophageal squamous cell carcinoma (ESCC) is a genetically complex tumor type and a major cause of cancer related mortality. Although distinct genetic alterations have been linked to ESCC development and prognosis, the genetic alterations have not gained clinical applicability. We applied array-based comparative genomic hybridization (aCGH) to obtain a whole genome copy number profile relevant for identifying deranged pathways and clinically applicable markers.
A 32 k aCGH platform was used for high resolution mapping of copy number changes in 30 stage I-IV ESCC. Potential interdependent alterations and deranged pathways were identified and copy number changes were correlated to stage, differentiation and survival.
Copy number alterations affected median 19% of the genome and included recurrent gains of chromosome regions 5p, 7p, 7q, 8q, 10q, 11q, 12p, 14q, 16p, 17p, 19p, 19q, and 20q and losses of 3p, 5q, 8p, 9p and 11q. High-level amplifications were observed in 30 regions and recurrently involved 7p11 (EGFR), 11q13 (MYEOV, CCND1, FGF4, FGF3, PPFIA, FAD, TMEM16A, CTTS and SHANK2) and 11q22 (PDFG). Gain of 7p22.3 predicted nodal metastases and gains of 1p36.32 and 19p13.3 independently predicted poor survival in multivariate analysis.
aCGH profiling verified genetic complexity in ESCC and herein identified imbalances of multiple central tumorigenic pathways. Distinct gains correlate with clinicopathological variables and independently predict survival, suggesting clinical applicability of genomic profiling in ESCC.
食管鳞状细胞癌(ESCC)是一种基因复杂的肿瘤类型,也是癌症相关死亡的主要原因。尽管不同的基因改变与ESCC的发生发展及预后相关,但这些基因改变尚未获得临床应用价值。我们应用基于芯片的比较基因组杂交技术(aCGH)来获取与识别紊乱通路及临床适用标志物相关的全基因组拷贝数图谱。
采用32k aCGH平台对30例I-IV期ESCC的拷贝数变化进行高分辨率定位。识别潜在的相互依赖改变和紊乱通路,并将拷贝数变化与分期、分化及生存情况相关联。
拷贝数改变影响了基因组中位数19%的区域,包括染色体区域5p、7p、7q、8q、10q、11q、12p、14q、16p、17p、19p、19q和20q的反复扩增以及3p、5q、8p、9p和11q的缺失。在30个区域观察到高水平扩增,且反复涉及7p11(EGFR)、11q13(MYEOV、CCND1、FGF4、FGF3、PPFIA、FAD、TMEM16A、CTTS和SHANK2)和11q22(PDFG)。7p22.3的扩增预测有淋巴结转移,而1p36.32和19p13.3的扩增在多变量分析中独立预测不良生存。
aCGH分析证实了ESCC的基因复杂性,并在此识别出多个核心致癌通路的失衡。不同的扩增与临床病理变量相关,并独立预测生存,提示基因组分析在ESCC中具有临床应用价值。